Francesco Mazzarelli

Dr. Francesco Mazzarelli

Casa Sollievo della Sofferenza Hospital IRCCS
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2022 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
TCTommaso Colangelo
Tommaso Colangelo
ACAnnalucia Carbone
Annalucia Carbone
FMFrancesco Mazzarelli
Francesco Mazzarelli
Roberto CuttanoRoberto Cuttano
Roberto Cuttano
EDElisa Dama
Elisa Dama
Gianluigi MazzoccoliGianluigi Mazzoccoli
Gianluigi Mazzoccoli

25 June 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
VMValentina Melocchi
Valentina Melocchi
EDElisa Dama
Elisa Dama
FMFrancesco Mazzarelli
Francesco Mazzarelli
RCRoberto Cuttano
Roberto Cuttano
TCTommaso Colangelo
Tommaso Colangelo
Fabrizio BianchiFabrizio Bianchi
Fabrizio Bianchi

15 December 2020 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
EDElisa Dama
Elisa Dama
VMValentina Melocchi
Valentina Melocchi
FMFrancesco Mazzarelli
Francesco Mazzarelli
TCTommaso Colangelo
Tommaso Colangelo
Roberto CuttanoRoberto Cuttano
Roberto Cuttano
Fabrizio BianchiFabrizio Bianchi
Fabrizio Bianchi
Lung cancer burden can be reduced by adopting primary and secondary prevention strategies such as anti-smoking campaigns and low-dose CT screening for high risk subjects (aged >50 and smokers >30 packs/year). Recent CT screening trials demonstrated a stage-shift towards earlier stage lung cancer and reduction of mortality (~20%). However, a sizable fraction of patients (30–50%) with early stage disease still experience relapse and an adverse prognosis. Thus, the identification of effective prognostic biomarkers in stage I lung cancer is nowadays paramount. Here, we applied a multi-tiered approach relying on coupled RNA-seq and miRNA-seq data analysis of a large cohort of lung cancer patients (TCGA-LUAD, n = 510), which enabled us to identify prognostic miRNA signatures in stage I lung adenocarcinoma. Such signatures showed high accuracy (AUC ranging between 0.79 and 0.85) in scoring aggressive disease. Importantly, using a network-based approach we rewired miRNA-mRNA regulatory networks, identifying a minimal signature of 7 miRNAs, which was validated in a cohort of FFPE lung adenocarcinoma samples (CSS, n = 44) and controls a variety of genes overlapping with cancer relevant pathways. Our results further demonstrate the reliability of miRNA-based biomarkers for lung cancer prognostication and make a step forward to the application of miRNA biomarkers in the clinical routine.

1 July 2019 in Cancer Research
Verified
Conference Paper
Closed access
TCTommaso Colangelo
Tommaso Colangelo
FMFrancesco Mazzarelli
Francesco Mazzarelli
RCRoberto Cuttano
Roberto Cuttano
EDElisa Dama
Elisa Dama
VMValentina Melocchi
Valentina Melocchi
FBFabrizio Bianchi
Fabrizio Bianchi
MicroRNAs (miRNAs) are small, highly conserved noncoding RNA molecules involved in the regulation of gene expression. MicroRNAs are resistant to harsh conditions and stably exist in body fluids (e.g. saliva, urine, breast milk, blood). Circulating cell-free miRNAs (cf-miRNA) were shown to be effective biomarkers for the early diagnosis of cancer. Furthermore, cf-miRNA were also found in exosomes that are nano-sized extracellular vesicles which exchange molecular information among cells. However, the understanding of origin of cf-miRNAs and of biological function still remains elusive. We recently identified a signature of cf-miRNAs diagnostic for lung cancer which we now hypothesize being released by lung cancer cells (EP-cf-miRNA) and by tumor microenvironment (TME-cf-miRNA). In particular, two cf-miRNAs, miR-29a and 223-3p, were selected as prototypes of EP- and TME-cf-miRNAs for further investigations.We found that the expression of miR-223-3p was higher in TME than in cancer cells of a cohort of 19 lung adenocarcinoma. In contrast, miR-29a-3p was frequently overexpressed (≥2 fold) in cancer cells. Interestingly, the serum concentration of cf-miR-29a was lower than miR-223-3p and this also in exosomes.We next investigated the expression profile of miR-29a/223-3p in a panel of lung normal and adenocarcinoma cell lines (N=14). miR-29a/223-3p were both expressed intracellularly and in exosomes. Of note, the miR-29a expression level resembles that observed in lung cancer cells from FFPE samples. Conversely, miR-223-3p expression was lower in the adenocarcinoma cell lines which further confirm a more TME origin. We are now expanding our analysis by screening the whole set of cf-miRNAs by high-throughput qPCR profile (OpenArray technology) and by applying laser capture microdissection to investigate single cancer epithelial cells and TME. Our work provides proof of principle demonstration of an effective approach to investigate cf-miRNA origin to unravel the role of cf-miRNA in lung adenocarcinoma. Citation Format: Tommaso Colangelo, Francesco Mazzarelli, Roberto Cuttano, Elisa Dama, Valentina Melocchi, Paolo Graziano, Fabiola Fiordelisi, Fabrizio Bianchi. Investigating the origin and function of circulating miRNA in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2582.

21 July 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
TCTommaso Colangelo
Tommaso Colangelo
PPPatrizio Panelli
Patrizio Panelli
FMFrancesco Mazzarelli
Francesco Mazzarelli
FTFrancesco Tamiro
Francesco Tamiro
VMValentina Melocchi
Valentina Melocchi
Fabrizio BianchiFabrizio Bianchi
Fabrizio Bianchi
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive T-cell malignancy characterized by genotypically-defined and phenotypically divergent cell populations, governed by adaptive landscapes. Clonal expansions are associated to genetic and epigenetic events, and modulation of external stimuli that affect the hierarchical structure of subclones and support the dynamics of leukemic subsets. Recently, small extracellular vesicles (sEV) such exosomes were also shown to play a role in leukemia. Here, by coupling miRNome, bulk and single cell transcriptome profiling, we found that T-ALL-secreted sEV contain NOTCH1-dependent microRNAs (EV-miRs), which control oncogenic pathways acting as autocrine stimuli and ultimately promoting the expansion/survival of highly proliferative cell subsets of human T-cell leukemias. Of interest, we found that NOTCH1-dependent EV-miRs mostly comprised members of miR-17-92a cluster and paralogues, which rescued in vitro the proliferation of T-ALL cells blocked by γ-secretase inhibitors (GSI) and regulate network of genes characterizing patients with relapsed/refractory early T-cell progenitor (ETP) ALLs. All these findings suggest that NOTCH1 dependent EV-miRs may sustain the growth/survival of immunophenotypically defined cell populations, altering the cell heterogeneity and the dynamics of T-cell leukemias in response to conventional therapies.